IGF2BP3 and triple-negative breast carcinoma: These mediators were identified as IGF2BP3 targets by PAR-CLIP studies and were subsequently validated in triple-negative breast cancer cells; however, the exact mechanisms of IGF2BP3-mediated regulation are still unknown.